Edition:
United States

Eiger BioPharmaceuticals Inc (CLDN.OQ)

CLDN.OQ on NASDAQ Stock Exchange Global Market

--USD
--
Change (% chg)

-- (--)
Prev Close
--
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
131,249
52-wk High
$16.96
52-wk Low
$6.20

CLDN.OQ

Chart for CLDN.OQ

About

Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe... (more)

Overall

Beta: --
Market Cap(Mil.): $112.65
Shares Outstanding(Mil.): 8.36
Dividend: --
Yield (%): --

Financials

  CLDN.OQ Industry Sector
P/E (TTM): -- 43.83 36.83
EPS (TTM): -19.27 -- --
ROI: -78.28 -0.29 13.93
ROE: -78.56 -2.99 14.84

BRIEF-Eiger Biopharmaceuticals prices public offering of common stock

* Eiger Biopharmaceuticals announces pricing of public offering of common stock

Aug 18 2016

BRIEF-Eiger Biopharmaceuticals Q2 loss per share $1.87

* Eiger Biopharmaceuticals reports second quarter 2016 financial results

Aug 10 2016

BRIEF-Eiger Biopharmaceuticals CFO Welch buys 2500 shares of common stock at avg price of $19.79/shr - SEC filing

* CFO James Welch reports purchase of 2500 shares of company's common stock at average price of $19.79 per share - SEC filing Source text - http://1.usa.gov/28QGX7q Further company coverage:

Jun 22 2016

BRIEF-Eiger Biopharmaceuticals files for mixed shelf of up to $125 mln

* Eiger Biopharmaceuticals Inc files for mixed shelf of up to $125 million

Jun 17 2016

BRIEF-Eiger Biopharmaceuticals Q1 loss per share $10.42

* Eiger Biopharmaceuticals provides corporate update and reports first quarter 2016 financial results

May 16 2016

BRIEF-Eiger Biopharmaceuticals says license of worldwide rights to Pegylated Interferon lambda-1a from Bristol-Myers Squibb

* Eiger biopharmaceuticals announces license of worldwide rights to pegylated interferon lambda-1a from bristol-myers squibb

Apr 20 2016

BRIEF-Vivo Ventures reports 23 pct stake in Eiger Biopharmaceuticals

* Vivo Ventures Vi, LLC reports 23.0% stake in Eiger Biopharmaceuticals as of March 22, 2016 - SEC filing Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Apr 01 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : Thomson Reuters Stock Report
$25.00
Provider : Stock Traders Daily
$20.00
Provider : New Constructs, LLC
$25.00
Provider : Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.